RxSight (RXST) Cash from Financing Activities (2020 - 2026)

RxSight's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$336000.0 for Q1 2026.

• Quarterly Cash from Financing Activities rose 54.29% year-over-year to -$336000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 98.03% YoY) and the FY2025 annual result came in at $1.9 million, down 98.49% from the prior year.
• Cash from Financing Activities was -$336000.0 for Q1 2026 at RxSight, down from $1.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $111.5 million in Q2 2024 and bottomed at -$8.2 million in Q3 2023.
• A 5-year average of $11.3 million and a median of $891000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 66737.76% in 2023, while the deepest fall reached 1709.67% in 2023.
• RxSight's Cash from Financing Activities stood at $6.3 million in 2022, then sank by 43.52% to $3.6 million in 2023, then declined by 16.45% to $3.0 million in 2024, then tumbled by 64.28% to $1.1 million in 2025, then plunged by 131.61% to -$336000.0 in 2026.
• Business Quant data shows RXST's Cash from Financing Activities at -$336000.0 in Q1 2026, $1.1 million in Q4 2025, and -$530000.0 in Q3 2025.